53 related articles for article (PubMed ID: 10510383)
21. Pharmaceutical strategies utilizing recombinant human serum albumin.
Chuang VT; Kragh-Hansen U; Otagiri M
Pharm Res; 2002 May; 19(5):569-77. PubMed ID: 12069157
[TBL] [Abstract][Full Text] [Related]
22. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.
Coloma MJ; Lee HJ; Kurihara A; Landaw EM; Boado RJ; Morrison SL; Pardridge WM
Pharm Res; 2000 Mar; 17(3):266-74. PubMed ID: 10801214
[TBL] [Abstract][Full Text] [Related]
23. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
24. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
Ng PP; Dela Cruz JS; Sorour DN; Stinebaugh JM; Shin SU; Shin DS; Morrison SL; Penichet ML
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10706-11. PubMed ID: 12149472
[TBL] [Abstract][Full Text] [Related]
25. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.
Shin SU; Wu D; Ramanathan R; Pardridge WM; Morrison SL
J Immunol; 1997 May; 158(10):4797-804. PubMed ID: 9144494
[TBL] [Abstract][Full Text] [Related]
26. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
28. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
[TBL] [Abstract][Full Text] [Related]
29. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
30. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
31. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
Boado RJ
Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotides for target validation in the CNS.
Ho SP; Hartig PR
Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
